Medtronic PLC $MDT Shares Sold by Edgar Lomax Co. VA

Edgar Lomax Co. VA trimmed its holdings in Medtronic PLC (NYSE:MDT) by 22.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 260,930 shares of the medical technology company’s stock after selling 76,155 shares during the period. Medtronic accounts for about 1.9% of Edgar Lomax Co. VA’s holdings, making the stock its 19th biggest holding. Edgar Lomax Co. VA’s holdings in Medtronic were worth $24,851,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MDT. Perennial Investment Advisors LLC purchased a new position in Medtronic in the 3rd quarter worth approximately $206,000. Smith Moore & CO. grew its position in shares of Medtronic by 5.1% in the third quarter. Smith Moore & CO. now owns 13,275 shares of the medical technology company’s stock valued at $1,264,000 after purchasing an additional 639 shares in the last quarter. Orion Porfolio Solutions LLC increased its holdings in shares of Medtronic by 28.0% in the third quarter. Orion Porfolio Solutions LLC now owns 121,441 shares of the medical technology company’s stock valued at $11,566,000 after purchasing an additional 26,565 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its position in Medtronic by 0.4% during the third quarter. Stonebridge Capital Advisors LLC now owns 182,724 shares of the medical technology company’s stock worth $17,403,000 after buying an additional 639 shares in the last quarter. Finally, Advisory Alpha LLC boosted its stake in Medtronic by 19.6% during the third quarter. Advisory Alpha LLC now owns 3,184 shares of the medical technology company’s stock worth $304,000 after buying an additional 521 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Medtronic Price Performance

Medtronic stock opened at $92.96 on Friday. The company’s 50 day simple moving average is $98.80 and its 200-day simple moving average is $96.95. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $119.35 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 2.40 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the firm earned $1.38 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MDT. TD Cowen reiterated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Mizuho raised shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Morgan Stanley boosted their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).